Overview

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mirati Therapeutics Inc.
Treatments:
Ipilimumab
Nivolumab
Pembrolizumab